Blocking ELISA

Plates are blocked with 300 xl/wcll of ELISA Block (ELISA Wash with 1% bovine serum albumin [BSA]) for a minimum of 1 h at room temperature. 

The antibody solution (1.6x10 M) and substrate solutions with various concentration from 10 M to 10 M were mixed on a BSA-coated plate. The mixed solution of antibodies and substrates was allowed to stand for 1 day at room temperature, and then transported to the ELISA plates pre-coated with BSA-hapten and BSA blocking buffer. Absorbance at 405 nm for the resulting enzymatic hydrolysis product (p-nitrophenolate) by alkalinephosphatase of the second antibody was recorded on an Immuno-Mini NJ-2300 to determine the amount of antibody bound to BSA-hapten. 

Fig. 8 Absorbance of an ELISA test where the 2F4 binds pectins with different degrees of methylesterifi-cation (R%, random or B%, block distribution)...

Figure 1 Schematic sequence of the direct and indirect competitive ELISA. The principle difference is that for direct competitive immunoassay, the well is coated with primary antibody directly, and for indirect competitive immunoassay, the well is coated with antigen. Primary antibody (Y), blocking protein (Y), analyte (T), analyte-tracer ( ), enzyme labeled secondary antibody ), color development ( J)...

Figure 15.9 The results of capture ELISA on native RNase A and formalin-treated RNase A. Right panel, native RNase A (curve 1) and unfractionated formalin-treated RNase A (curve 2). Left panel, individual fractions of formalin-treated RNase A monomer (curve 3), dimmer (curve 4), trimer (curve 5), tetramer (curve 6), and a mixture of oligomers with >5 cross-linked proteins (curve 7). The ELISA plate wells were coated with monoclonal antibody against bovine pancreatic RNase A (1 pg/mL) overnight at 4°C and then blocked with bovine serum albumin. The wells were incubated for lh at 37°C in the presence of various concentrations of antigen in lOOpL of PBS. After washing, each plate well received a 1 4000 dilution of horseradish peroxidase conjugated rabbit polyclonal anti-RNase A antibody followed by incubation at ambient temperature for lh. After washing, detection was achieved using a mixture of 2,2,-azino-di-(3-ethylbenzthiazoline-6-sulphonate) and hydrogen peroxide. Absorbance was monitored at 405 nm. See Rait etal.11 for details.

Some patients will have repeatedly nonspecific reactivity in an ELISA assay, since the HIV-1 antigen used for the antibody assays is produced in cultured human T cells. It is not unexpected that occasional false positive assays occur in human sera from individuals with autoimmune diseases a history of multiple pregnancies or multiple transfusions or antibodies to certain class II histocompatibility antigens (especially HLA-DR4). Block reagents have been added to specimen diluents to minimize cross-reactions in these sera. This necessitates the use of confirmatory tests, especially the Western blot. With the use of both ELISA and Western blots, false positives decrease to less than 1 per 100,000. 

An overview of the procedure for an ELISA is as follows Fix cells onto the well of the plate block the cells and well surface to prevent nonspecific binding incubate the cells in the presence of the primary antibody rinse away any unbound antibody incubate the cells in the presence of the enzyme-linked secondary antibody rinse away unbound antibody add enzyme subshate read the color reaction with a plate reader. 

Assays utilized conventional ELISA processing except that the reagent volumes were greatly reduced, ranging from 25- to 50-pL well additions. Following a 1-hr block in casein, the monoclonal detection antibody was incubated an additional hour at room temperature. The assay sensihvity from the micro-ELISA was approximately 13.4 ng/mL for rabbit IgG — a result similar to that reported by Silzel et al. (1998). The benefit of the "array of arrays" approach is that 96 samples could be processed for multiple (36 to 144) analytes within the same time interval as a standard single-analyte ELISA. 

However, not all antibody detected by ELISA corresponds to the antibody molecule that blocks the biological activity or active sites of the therapeutic protein. These neutralizing (blocking) antibodies are only a small fraction of the binding antibody population. Different cell- and receptor-based neutralizing antibody assays are developed for different protein drugs. 

For ELISA, an enzyme is linked chemically to the antibody. The labeled antibody is allowed to bind to the unlabeled antigen, under conditions where nonspecific adsorption is blocked, and any unbound antibody and other proteins are washed away. Binding is detected by a reaction that converts a colorless substrate into a colored reaction product. The color change can be read directly in the reaction tray, making data collection very easy, and ELISA also avoids the hazards of radioactivity. This makes ELISA the preferred method for most direct-binding assays (Plested et al. 2003). 

An ELISA (enzyme-linked immunosorbent assay) allows for rapid screening and quantification of the presence of an antigen in a sample (Fig. 5-28b). Proteins in a sample are adsorbed to an inert surface, usually a 96-well polystyrene plate. The surface is washed with a solution of an inexpensive nonspecific protein (often casein from nonfat dry milk powder) to block proteins introduced in subsequent steps from also adsorbing to these surfaces. The surface is then treated with a solution containing the primary antibody—an antibody against the protein of interest. Unbound antibody is washed away and the surface is treated with a solution containing antibodies against the primary antibody. These secondary antibodies have been linked to an enzyme that catalyzes a reaction that forms a colored product. After unbound secondary antibody is washed away, the substrate of the antibody-linked enzyme is added. Product formation (monitored as color intensity) is proportional to the concentration of the protein of interest in the sample. 

In an immunoblot assay (Fig. 5-28c), proteins that have been separated by gel electrophoresis are transferred electrophoretically to a nitrocellulose membrane. The membrane is blocked (as described above for ELISA), then treated successively with primary... 

When unfixed cells or frozen sections are used for ELISA, it may be necessary to block endogenous alkaline phosphatase activity, and in this case, include 0.1 mil/ levamisole in the substrate solution. 

Coat ELISA plates as for the panning procedure, and block with 200 pL PBS containing 1 % BSA for 1 h... 

Discard blocking buffer. Wash plate three times (see step 3). (Optimization of the concentration of the enzyme-conjugated antigen is required for initially establishing the competitive ELISA see Subheading 3.2.). 

Mohammad, K. and Esen, A. (1989) A blocking agent and a blocking step are not needed in ELISA, immunostaining dot-blots and western blots. J. Immunol. Methods 117, 141-145. 

Vogt RF, Jr, Phillips DL, Henderson LO, Whitfield W, Spierto FW. Quantitative differences among various proteins as blocking agents for ELISA microtiter plates. J Immunol Methods 1987 101(1) 43 50. 

Plasma or serum samples are diluted 1/200 with ELISA Block. 

ELISA Block is removed by flicking and blotting as before (see Step 3). 

---